No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:03.394Z. Latest historical point 2024-03-01. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Immuneering Corporation (IMRX) stock was $4.04 as of Oct 6, 2026, 10:00 AM EDT, down 0.12% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -33.1% · 3-year avg -18.5%/yr · 5-year avg -32.8%/yr
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.29
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.27
vs Estimate
$-0.27
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IMRX | $146.48M | $4.04 | -0.12% | -33.09% | -32.77% | N/A | N/A |
| 2KRSA | $146.51M | $31.30 | +1.88% | +75.07% | -40.41% | N/A | vs IMRX |
| 3ACOG | $146.30M | $9.42 | +2.95% | +22.21% | N/A | N/A | vs IMRX |
| 4ABOS | $148.79M | $2.06 | -3.29% | +23.00% | -32.60% | N/A | vs IMRX |
| 5FBIOP | $141.70M | $18.00 | -0.55% | +144.21% | +0.05% | N/A | vs IMRX |
| 6CDXS | $153.28M | $1.43 | +2.52% | -45.12% | -44.64% | -11.05% | vs IMRX |
forward FY estimate
N/A
Consensus Rating
Based on 6 analysts
Average Price Target
$17.17
+325.4% upside
Low
$12.00
Current
$4.04
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.33 | $-0.31 | $-0.28 | 5 |
| Quarter ending Dec 2026 | $-0.37 | $-0.34 | $-0.31 | 5 |
| Quarter ending Mar 2027 | $-0.34 | $-0.34 | $-0.34 | 3 |
| Quarter ending Jun 2027 | $-0.36 | $-0.36 | $-0.36 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.21 | $-1.12 | $-1.06 | 6 |
| FY 2027 | $-1.37 | $-1.26 | $-1.09 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $21.27M | $21.27M | $21.27M | 7 |
| FY 2027 | $22.75M | $22.75M | $22.75M | 7 |
